Healthcare Industry News: Leksell Gamma Knife
News Release - September 14, 2006
Cooper University Hospital to Join Ranks of Top Neurosurgery Centers with New Leksell Gamma Knife(R) Perfexion(TM)ATLANTA and CAMDEN, N.J., Sept. 14 (HSMN NewsFeed) -- Brain surgery without a knife, gamma rays guided by robotic controls and 3D targeting that's as precise as a pinpoint sound like the inventions of science fiction, but this is no fiction - it's the new reality at Cooper University Hospital, which has purchased Leksell Gamma Knife® Perfexion(TM).
Cooper University Hospital, located in Camden, NJ, will be one of the first hospitals in the U.S., and the only one in New Jersey and the Delaware Valley, to offer patients the most advanced system ever for non-invasive treatment for brain disorders with the new Leksell Gamma Knife Perfexion. The ground-breaking system brings together the best of both worlds - innovations that make treatment faster and more accurate plus experience gained from treating almost half a million patients worldwide.
"Gamma Knife® surgery is known as the gold standard in stereotactic radiosurgery, and with good reason," said H. Warren Goldman, M.D., Ph.D., Chief of Neurosurgery and Director of the Cooper Neurological Institute. "With the technological advances that have been integrated into Leksell Gamma Knife Perfexion, we will be able to offer patients new options in treating brain disorders and brain tumors which are gentle, non-invasive and effective," Goldman added.
"The ability to shape the highly-focused radiation dose advances Leksell Gamma Knife Perfexion to the 'next level' by combining radiation oncology and neurosurgical expertise for the treatment of brain tumors and other brain disorders," said Samuel L. Hughes, M.D., Clinical Director, Department of Radiation Oncology. "The significant improvements in treatment delivery dramatically decrease patient treatment time and minimize the risk of radiation exposure to personnel."
Cooper expects to treat its first patient with Leksell Gamma Knife Perfexion in May of 2007.
Leksell Gamma Knife Perfexion automates treatment delivery so it's as easy as pushing a button. This ease of use, combined with robust software that simplifies complicated treatment plans, plus unmatched precision for treatment delivery, gives physicians tools that optimize their skills and allow them to treat patients as never before.
"You don't want to bathe the brain in radiation, so accuracy is extremely important," said Anthony DeCarolis, President and CEO of Elekta, Inc. and head of Elekta's operations in North America. "Often you see a multi-purpose radiation device being used to treat the brain, but that's not the optimum choice. Cooper University Hospital has demonstrated its commitment to patients by selecting Leksell Gamma Knife Perfexion, which is based on the worldwide acceptance of Gamma Knife surgery."
In August, the U.S. Food and Drug Administration (FDA) issued a 510(k) pre-market clearance for Leksell Gamma Knife Perfexion, allowing Elekta to market this innovative new system to the U.S. market.
About Cooper University Hospital
Cooper University Hospital is the leading provider of comprehensive health services, medical education and clinical research in southern New Jersey and the Delaware Valley. With over 550 physicians in over 75 specialties, Cooper is uniquely equipped to provide an almost unlimited number of medical services. As the clinical campus of the University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School at Camden, the hospital is committed to excellence in medical education, patient care and research.
Elekta is an international medical-technology group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.